195 related articles for article (PubMed ID: 23577085)
21. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
[TBL] [Abstract][Full Text] [Related]
22. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients.
An Q; Liu Y; Gao Y; Huang J; Fong X; Li L; Zhang D; Cheng S
Cancer Lett; 2002 Dec; 188(1-2):109-14. PubMed ID: 12406555
[TBL] [Abstract][Full Text] [Related]
23. O-6-methylguanine-DNA methyltransferase gene promoter methylation and lung cancer risk: A meta-analysis.
Yang Z; Li F
J Cancer Res Ther; 2016 Dec; 12(Supplement):C233-C236. PubMed ID: 28230024
[TBL] [Abstract][Full Text] [Related]
24. Determination of O⁶-methylguanine DNA methyltransferase promoter methylation in non-small cell lung cancer.
Ekim M; Caner V; Büyükpınarbaşılı N; Tepeli E; Elmas L; Bağcı G
Genet Test Mol Biomarkers; 2011 May; 15(5):357-60. PubMed ID: 21288129
[TBL] [Abstract][Full Text] [Related]
25. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
[TBL] [Abstract][Full Text] [Related]
26. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
[TBL] [Abstract][Full Text] [Related]
27. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
[TBL] [Abstract][Full Text] [Related]
29. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
Zhang Z; Yan S; Cui H; Chen H; Liu J
Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
Wang J; Wang B; Chen X; Bi J
Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
[TBL] [Abstract][Full Text] [Related]
31. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
32. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
34. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
Zhang Y; Miao Y; Yi J; Wang R; Chen L
Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
[TBL] [Abstract][Full Text] [Related]
35. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Wang Y; Zhang D; Zheng W; Luo J; Bai Y; Lu Z
Cancer; 2008 Mar; 112(6):1325-36. PubMed ID: 18286531
[TBL] [Abstract][Full Text] [Related]
36. Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC).
Feng H; Zhang Z; Qing X; Wang X; Liang C; Liu D
Exp Mol Pathol; 2016 Feb; 100(1):109-13. PubMed ID: 26681652
[TBL] [Abstract][Full Text] [Related]
37. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
39. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
[TBL] [Abstract][Full Text] [Related]
40. [Abnormality of p16 gene and its clinicopathological significance in non-small cell lung cancer].
Fu J; Zhang J; Zhang HW
Zhonghua Bing Li Xue Za Zhi; 2003 Apr; 32(2):133-6. PubMed ID: 12839675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]